New Triple-Drug cocktail aims to beat back tough leukemia
NCT ID NCT03661307
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a combination of three drugs—quizartinib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to find the safest dose and see if the combination improves remission rates. The trial is for patients who are older or whose cancer has returned.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
quizartinib, decitabine, and venetoclax
What this could lead to
If this works, it could offer a new treatment option for people with acute myeloid leukemia who cannot tolerate intensive chemotherapy.
What could go wrong
This is an early-phase trial with only 73 participants, so results may not apply to everyone. The drug combination may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact